IN2015DN00542A - - Google Patents
Info
- Publication number
- IN2015DN00542A IN2015DN00542A IN542DEN2015A IN2015DN00542A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A IN 542DEN2015 A IN542DEN2015 A IN 542DEN2015A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A
- Authority
- IN
- India
- Prior art keywords
- compositions
- disorders
- methods
- treating
- diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000023715 Ocular surface disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676530P | 2012-07-27 | 2012-07-27 | |
| US201361756321P | 2013-01-24 | 2013-01-24 | |
| PCT/US2013/052264 WO2014018856A1 (en) | 2012-07-27 | 2013-07-26 | Compositions and treatment for eye diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00542A true IN2015DN00542A (cs) | 2015-06-26 |
Family
ID=49997851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN542DEN2015 IN2015DN00542A (cs) | 2012-07-27 | 2013-07-26 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150216877A1 (cs) |
| EP (1) | EP2877184B1 (cs) |
| JP (1) | JP6209777B2 (cs) |
| KR (1) | KR102097663B1 (cs) |
| CN (2) | CN104661663A (cs) |
| AU (1) | AU2013295645B2 (cs) |
| BR (1) | BR112015001847A8 (cs) |
| CA (1) | CA2880027C (cs) |
| DK (1) | DK2877184T3 (cs) |
| ES (1) | ES2759781T3 (cs) |
| HU (1) | HUE046963T2 (cs) |
| IL (1) | IL236920B (cs) |
| IN (1) | IN2015DN00542A (cs) |
| MX (1) | MX362185B (cs) |
| NZ (1) | NZ704247A (cs) |
| PL (1) | PL2877184T3 (cs) |
| PT (1) | PT2877184T (cs) |
| SM (1) | SMT201900678T1 (cs) |
| WO (1) | WO2014018856A1 (cs) |
| ZA (1) | ZA201500561B (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| EP2968368B1 (en) | 2013-03-15 | 2017-08-09 | Glia LLC | Cranial delivery of pharmaceuticals |
| WO2015080758A1 (en) * | 2013-11-27 | 2015-06-04 | Al-Qahtani Ahmed H | Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| CN106794168A (zh) | 2014-07-21 | 2017-05-31 | 格利亚有限责任公司 | 用大麻素治疗放疗和化疗相关的认知或情感损伤的方法 |
| WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR101960023B1 (ko) * | 2016-12-21 | 2019-03-20 | 김보경 | 이산화탄소 발생 장치 |
| EP4103194A4 (en) * | 2020-02-12 | 2024-03-06 | Glia, Llc | PROGESTERONE COMBINATIONS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102656A (en) | 1983-07-29 | 1992-04-07 | The Mennen Company | Antiperspirant creams |
| US4937069A (en) | 1985-11-15 | 1990-06-26 | Bristol-Myers Squibb Company | Anhydrous semi-solid antiperspirant suspension |
| US5069897A (en) | 1987-10-16 | 1991-12-03 | The Proctor & Gamble Company | Antiperspirant creams |
| US6659985B2 (en) | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| US7572780B2 (en) | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
| US20080132475A1 (en) | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| JP5640207B2 (ja) * | 2007-10-08 | 2014-12-17 | セラオプティクスＴｈｅｒａｏｐｔｉｃｓ | 水性眼用処方物 |
| US20100016264A1 (en) | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| CN101757622A (zh) * | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | 一种眼部抗炎的药物组合物 |
| US10029013B2 (en) * | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
-
2013
- 2013-07-26 IN IN542DEN2015 patent/IN2015DN00542A/en unknown
- 2013-07-26 WO PCT/US2013/052264 patent/WO2014018856A1/en not_active Ceased
- 2013-07-26 CN CN201380039713.2A patent/CN104661663A/zh active Pending
- 2013-07-26 KR KR1020157004782A patent/KR102097663B1/ko active Active
- 2013-07-26 JP JP2015524465A patent/JP6209777B2/ja active Active
- 2013-07-26 MX MX2015001250A patent/MX362185B/es active IP Right Grant
- 2013-07-26 HU HUE13823485A patent/HUE046963T2/hu unknown
- 2013-07-26 PT PT138234851T patent/PT2877184T/pt unknown
- 2013-07-26 SM SM20190678T patent/SMT201900678T1/it unknown
- 2013-07-26 ES ES13823485T patent/ES2759781T3/es active Active
- 2013-07-26 DK DK13823485T patent/DK2877184T3/da active
- 2013-07-26 EP EP13823485.1A patent/EP2877184B1/en active Active
- 2013-07-26 CN CN201710063950.2A patent/CN107595857A/zh active Pending
- 2013-07-26 AU AU2013295645A patent/AU2013295645B2/en active Active
- 2013-07-26 US US14/417,640 patent/US20150216877A1/en not_active Abandoned
- 2013-07-26 PL PL13823485T patent/PL2877184T3/pl unknown
- 2013-07-26 CA CA2880027A patent/CA2880027C/en active Active
- 2013-07-26 NZ NZ704247A patent/NZ704247A/en unknown
- 2013-07-26 BR BR112015001847A patent/BR112015001847A8/pt not_active Application Discontinuation
-
2015
- 2015-01-25 IL IL236920A patent/IL236920B/en active IP Right Grant
- 2015-01-26 ZA ZA2015/00561A patent/ZA201500561B/en unknown
-
2016
- 2016-12-15 US US15/380,741 patent/US9925201B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2877184T3 (da) | 2019-12-09 |
| SMT201900678T1 (it) | 2020-03-13 |
| HUE046963T2 (hu) | 2020-04-28 |
| WO2014018856A1 (en) | 2014-01-30 |
| CA2880027A1 (en) | 2014-01-30 |
| EP2877184B1 (en) | 2019-09-04 |
| HK1210968A1 (en) | 2016-05-13 |
| JP6209777B2 (ja) | 2017-10-11 |
| CN107595857A (zh) | 2018-01-19 |
| PT2877184T (pt) | 2019-12-02 |
| ES2759781T3 (es) | 2020-05-12 |
| JP2015524434A (ja) | 2015-08-24 |
| US9925201B2 (en) | 2018-03-27 |
| MX2015001250A (es) | 2015-10-22 |
| IL236920B (en) | 2018-06-28 |
| KR102097663B1 (ko) | 2020-04-06 |
| KR20150038311A (ko) | 2015-04-08 |
| ZA201500561B (en) | 2016-04-28 |
| AU2013295645A1 (en) | 2015-02-05 |
| AU2013295645B2 (en) | 2017-08-24 |
| US20150216877A1 (en) | 2015-08-06 |
| MX362185B (es) | 2019-01-08 |
| CA2880027C (en) | 2021-12-07 |
| NZ704247A (en) | 2018-04-27 |
| PL2877184T3 (pl) | 2020-04-30 |
| EP2877184A4 (en) | 2016-03-30 |
| BR112015001847A8 (pt) | 2021-09-08 |
| US20170189413A1 (en) | 2017-07-06 |
| EP2877184A1 (en) | 2015-06-03 |
| CN104661663A (zh) | 2015-05-27 |
| BR112015001847A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00542A (cs) | ||
| EP4450130A3 (en) | Formulations of enzalutamide | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| EP3185876A4 (en) | Compositions and methods for treatment of neurological disorders | |
| EP2709672A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NETWORK GLAND DISEASES | |
| EP3024497A4 (en) | Methods and compositions for treating brain diseases | |
| HK1216175A1 (zh) | 治療性化合物和組合物 | |
| EP3160493A4 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| EP3182977A4 (en) | Compositions and methods to treat vision disorders | |
| EP3515444A4 (en) | COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION | |
| EP3086809A4 (en) | Compositions and methods of treating ocular diseases | |
| EP2782566A4 (en) | L-SERIN COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEEGENERATIVE ILLNESSES AND SUFFERING | |
| EP3082427A4 (en) | Compositions and methods for treatment of glaucoma | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EP3370709A4 (en) | USE OF PROTEASOME INHIBITORS FOR THE TREATMENT OF EYE DISEASES | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders | |
| HK40092664A (en) | Compositions and methods for treatment of neurological disorders | |
| EP3003341A4 (en) | Compositions and methods for treatment of retinal degenerative diseases | |
| HK40066377A (en) | Compositions and methods for treatment of neurological disorders | |
| EP2999464A4 (en) | Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms |